There were several other speakers during this first session of the day which focused on in vitro modeling. of the Nuffield Department of Clinical Neurosciences at the University of Oxford (pictured), provided data from her research on two C9orf72 i PSc lines she created.
Two such talks were given regarding the characterization of i PS cells created from C9orf72 patient samples. In one of her lines, she reported that it maintained a total of 1380 hexanucleotide repeats and in the other, 510 were maintained through the reprogramming process.
It is an FDA approved compound for the treatment of certain forms of epilepsy and, together with the Northeast ALS Consortium, a 120 person clinical trial is being planned at 12 NEALS sites.
However, this trial will provide an opportunity to begin to answer that question for the first time, at least in ALS research.It included important reports on the landscape of ALS in China, new data on military incidence of ALS from the US, and a conversation on whether head injuries (ie: concussions) alter the progression of ALS.China is the world’s most populous country with more than 1.3 billion people.However, more recent studies have now shown different cognitive and executive dysfunctions in PALS.In the US, it is now thought that at least 10% of PALS develop frontotemporal dementia in addition to the progressive neurodegenerative disease.